Abstract
We report on 2 recombinant (r) live vaccine candidates that use different strategies to improve cell-mediated immunity for TB control: (i) the current TB vaccine strain Mycobacterium bovis BCG, endowed with a pore-forming cytolysin; and (ii) rSalmonella typhimurium secreting a single immunodominant antigen shared by BCG and M. tuberculosis.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
BCG Vaccine / immunology*
-
Humans
-
Immunity, Cellular
-
Mice
-
Mycobacterium bovis / immunology
-
Mycobacterium tuberculosis / immunology
-
Salmonella typhimurium / immunology
-
Tuberculosis, Pulmonary / immunology*
-
Tuberculosis, Pulmonary / prevention & control
-
Vaccines, Attenuated / immunology
-
Vaccines, Synthetic / immunology
Substances
-
BCG Vaccine
-
Vaccines, Attenuated
-
Vaccines, Synthetic